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ABSTRACT. Background: Zinc is an important nutrient and is
necessary to maintain a multitude of physiologic processes. Min-
eral supplements that provide physiologic doses of zinc may be
used when dietary zinc is inadequate. Zinc is also used in
pharmacologic doses to treat zinc deficiency and diseases such
as Wilson’s disease and acrodermatitis enteropathica. Although
there are several zinc salts available, they are not equal in solu-
bility, which is thought to be a key factor in zinc absorption.
Moreover, the solubility of the salts is affected by pH, which may
vary between pH 1 and 7 under various physiologic conditions in
the stomach. The objectives of this 2-way 4-phase crossover study
were to evaluate the effect of high (&ge;5) and low (&le;3) intragastric
pH on the absorption of zinc from the acetate and oxide salt in
young healthy volunteers. Methods: After a 9-hour fast, 10 healthy
subjects (5 males and 5 females) were given a single oral dose of
50 mg of elemental zinc as the acetate or the oxide salt and un-
der either high or low intragastric pH conditions. In all phases, a
Heidelberg capsule pH detector-transmitter was used to continu-
ously monitor intragastric pH. During the high pH phases, single
oral doses of famotidine 40 mg oral suspension were adminis-
tered before the zinc to raise the intragastric pH above 5.
Intragastric pH &le; 3 was maintained in the low pH phases. Re-
sults: The mean plasma zinc area under the curve for zinc acetate
at low pH (AL), zinc acetate at high pH (AH), zinc oxide at low pH
(OL), and zinc oxide at high pH (OH) were 524, 378, 364, and 66 &mu;g
x h/dL, respectively. The highest zinc plasma concentrations oc-
curred with the acetate salt at a low intragastric pH, while the low-
est plasma concentrations occurred with the oxide salt at a high
intragastric pH. The importance of pH to the dissolution of these
salts was verified by in vitro tests. Twenty-four-hour urinary zinc
excretion was the highest for the AL phase and lowest for the OH
phase. Conclusion: This study indicates that intragastric pH and
salt solubility-dissolution are important in the oral absorption of
zinc. Specifically, the oxide salt is not an appropriate zinc salt to
use in those patients with elevated intragastric pH. (Journal of
Parenteral and Enteral Nutrition 19:393-397, 1995)
Zinc, at required dietary concentrations, is important in
the maintenance of homeostasis. If dietary zinc is inad-
equate, preparations containing physiologic doses of zinc
may be used as a supplement. Zinc is also used in
pharmacologic doses to treat disease. Zinc participates in
many enzymatic processes involving bone formation, cell
membrane stabilization, host defense, dark adaptation and
night vision, and a variety of factors related to tissue
growth. It is absorbed throughout the gastrointestinal (GI)
tract with the highest rate of absorption occurring in the
jejunum Failure to absorb adequate amounts of zinc can
lead to zinc deficiency, which is manifested by growth re-
tardation, hypogonadism, alopecia, skin lesions, diarrhea,
mental depression, night blindness, altered taste sensa-
tion, impaired wound healing, and T-lymphocyte dysfunc-
tion.
Multivitamin and mineral preparations, which provide
4 to 15 mg of elemental zinc per dose, are often given to
prevent zinc deficiency due to inadequate dietary zinc. The
most commonly used zinc salt in these preparations is the
oxide. In pharmacologic doses, Newsome et ah found zinc
sulfate to be beneficial in the treatment of macular degen-
eration. These findings, although not confirmed, have
prompted an increase in the use of zinc to treat this eye
disorder of the elderly. Daily doses of up to 150 mg of el-
emental zinc as the acetate or sulfate salt are used to treat
Wilson’s disease.:3..! Zinc is also used as a supplement in
sickle cell disease and is used in the treatment of
acrodermatitis enteropathica.’ 5
The increasing use of zinc in the prevention and treat-
ment of disease necessitates more defmitive information
regarding factors that may affect the absorption of vari-
ous orally administered zinc salts. One factor that may be
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important in determining the extent of absorption is the
solubility of the zinc salt used. The solubilities of the most
frequently used salts vary from very soluble (sulfate and
chloride) and freely soluble (acetate) to practically in-
soluble (carbonate and oxide).6 Intragastric pH may also
affect zinc absorption because insoluble zinc salts are solu-
bilized by conversion to zinc chloride in the presence of
gastric acid.
The effect of pH and dissolution on zinc absorption have
not been well evaluated. Oelshlegel and Brewer’ reported
that plasma zinc concentrations after ingesting 25 mg of
elemental zinc as the sulfate, acetate, or carbonate salt,
did not differ significantly between the acetate and sul-
fate salts, but zinc absorption from the carbonate salt was
significantly lower. Prasad et all studied zinc absorption
from the sulfate, acetate, and oxide salts (equivalent to 50
mg of elemental zinc) in 10 healthy volunteers . Like
Oelshlegel and Brewer, 7 they found that zinc was absorbed
to a significantly greater extent from the more soluble
sulfate and acetate salts than from the practically insoluble
oxide salt and that there was no difference in zinc absorp-
tion between the sulfate and acetate salts.
The degree of intragastric acidity may be an important
factor affecting the absorption of zinc.9 To date there has
been only one published report investigating the role of
gastric acid in zinc absorption. Stumiolo et all’ studied the
influence of gastric acid secretion on intestinal zinc (as
the sulfate salt) absorption in healthy volunteers pretreated
with oral histamine-2 receptor antagonists (H2RAs),
cimetidine and ranitidine. A statistically significant reduc-
tion in zinc absorption occurred after pretreatment with
cimetidine and ranitidine when compared with no treat-
ment. It was concluded that intragastric acid plays a role
in the extent of zinc absorption in humans.
The objectives of the current study were to evaluate the
effect of high (~5) and low (~3) intragastric pH on the
absorption of zinc from the acetate and oxide salt in young
healthy volunteers using continuous intragastric pH moni-
toring.
MATERIALS AND METHODS
Zinc Acetate and Oxide
Zinc acetate was selected because of its increased use as an alter-
native to the sulfate salt, which frequently causes dyspepsia and nau-
sea. The acetate salt is currently used in the treatment of patients with
Wilson’s disease who take zinc to prevent copper reaccumulation. Zinc
oxide was selected because it is a salt frequently used by the pharma-
ceutical industry as a dietary supplement in multivitamin and mineral
preparations. The acetate and the oxide salts also present useful con-
trasts in aqueous solubility, with the acetate salt being freely soluble
and the oxide salt being practically insoluble.
Zinc acetate capsules, containing 50 mg (lot #9730) of elemental
zinc, were provided by the Lemmon Company (Sellersville, PA). Zinc
oxide capsules were prepared by the Investigational Drug Service at
University Hospital using zinc oxide powder USP (Mallinckrodt, lot
#8824KJSG), magnesium stearate NF (Lemmon Co, stock #4031), and
corn starch (Redried Starch B) NF (Lemmon Co, stock #4111). The
magnesium stearate NF and corn starch NF were provided by the
Lemmon Company from stocks used to prepare zinc acetate capsules.
This ensured identical inert ingredients in the zinc acetate and zinc
oxide capsules. Zinc content was verified according to USP standards.
Volunteer Selection
Ten healthy volunteers, 5 females (20.4 -~ 2.1 years of age, mean ±
SD) and 5 males (23.8 - 4.0 years of age, mean -~ SD), participated in
this study. All subjects were nonsmokers, within 20% of ideal body
weight, and were judged to be in good physical condition on the basis
of medical history, physical examination, blood chemistry, complete
blood count, and urinalysis. Subjects were asked to refrain from tak-
ing any vitamin or mineral supplement 30 days before and during the
entire study. None of the subjects were on any chronic medication with
the exception of oral contraceptives. The participants were asked not
to take any other medication or to consume ethanol 2 days before and
during each treatment phase. The Institutional Review Board of the
University of Michigan approved the study protocol and all subjects
gave written informed consent. The study was conducted at the Gen-
eral Clinical Research Center (GCRC) at the University of Michigan
Hospital.
pH Measuring System
A radiotelemetric device, the Heidelberg capsule (HC), was used to
continuously determine intragastric pH. The details of this method have
been previously described.ll Briefly, the HC consists of a battery oper-
ated transmitter housed in an acrylic case about 7 x 20 mm. The bat-
tery was activated by immersion in normal saline the morning of each
study. The capsule was calibrated immediately before the study, using
pH 1 and 7 buffer solutions maintained at a temperature of 37°C. The
capsule was tethered using surgical thread (Supramid Extra 2-0, S.
Jackson Inc, Alexandria, VA) to ensure a fixed location of the capsule
within the stomach during the study. The subject was asked to swal-
low the capsule with 90 mL of deionized water. If the subject had diffi-
culty swallowing the HC, an additional 60 mL of water was adminis-
tered. An antenna-receiver strapped around the midriff of the subject
was used to detect the radio signal transmitted by the capsule, which
is then converted to pH and recorded continuously as a function of
time on an analog recorder. At the end of each study, the subject re-
trieved the HC orally and the capsule’s response to pH 1 and 7 buffers
were verified against prestudy values. The recalibration was required
to be within 0.5 pH units of prestudy values for the results to be in-
cluded in the analysis.
Experimental Design
The study was performed in a two-way crossover, four-phase de-
sign. The washout period between treatments was at least 7 days. The
four phases were as follows: (1) zinc acetate administered to subjects
pretreated with a single dose of famotidine 40 mg oral suspension
(Pepcid oral suspension, Merck & Co, Inc, West Point, PA, lot #W0745)
to raise the intragastric pH ~ 5 (acetate high pH = AH), (2) zinc oxide
administered to subjects pretreated with a single oral dose of famotidine
40 mg oral suspension to raise the intragastric pH ~ 5 (oxide high pH =
OH), (3) zinc acetate administered to subjects with an intragastric pH
::5; 3 (acetate low pH = AL), and (4) zinc oxide administered to subjects
with an intragastric pH < 3 (oxide low pH = OL). Each subject was
given a single oral dose of either zinc acetate or zinc oxide equivalent
to 50 mg of elemental zinc. The order of the two salts given was ran-
domized. Subjects fasted from 9 PM the night before the first day of the
study (day 1). Subjects came to the GCRC at 12 noon for lunch and 5 PM
for dinner on day 1. After dinner the subjects were admitted as inpa-
tients to the GCRC. Subjects were each given a snack to be eaten at
8:30 PM. They were instructed to fast throughout the day except for
water, which could be taken as desired, and the scheduled meals. On
day 2 of the study, an indwelling catheter was inserted into a forearm
vein and approximately 5 mL of blood was collected at 6 AM for baseline
zinc concentration. The tethered HC was then swallowed with 90 mL
of deionized water and its position was fixed by taping the tether thread
to the subject’s cheek after the capsule had traveled at least 45 cm.
Correct capsule position in the stomach was verified by a combination
of tether length and a pH of <3 for at least 10 minutes.
High intragastric pH studies. Famotidine was selected because of its
potent inhibitory effects on gastric acid and because it does not con-
tain an imidazole group that has been shown to be a zinc ligand.12 The
imidazole portion of drugs such as cimetidine and omeprazole have
the potential to increase zinc absorption.
During the high intragastric pH (~5) phases, subjects received 40
mg of famotidine oral suspension with 60 mL of deionized water. After
45 minutes an additional 60 mL of water was given. Water administra-
tion was repeated every 15 minutes until the pH remained above 5 for
at least 10 minutes. A dose of zinc acetate or zinc oxide equivalent to
50 mg of elemental zinc was then administered with 120 mL of deion-
ized water. Just before zinc administration a 24-hour urine collection
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was begun. Intragastric pH was monitored for 4 hours after zinc ad-
ministration. To meet the study criteria, the pH had to be ~5 for at
least 80% of the first hour after zinc administration. Beginning 1 hour
after the administration of the zinc dose, 5 mL of blood was collected
hourly for 8 hours. Four hours after zinc administration, the HC was
retrieved orally by the subject and the capsule was recalibrated. Each
subject consumed the same lunch and dinner, as on day 1, at 4 and 8
hours after zinc administration. After dinner, the subjects were permit-
ted to leave the GCRC and were given a snack to be consumed at 8:30
P~s. Subjects returned to the GCRC at a predetermined time on day 3 to
complete the after zinc administration 24-hour urine collection.
Low intragastric pH studies. The same procedure as outlined above
was followed for the low pH phase of each zinc salt, except that
famotidine was not administered. The low pH phase followed the high
pH phase so that the water consumption could be duplicated. For the
low pH criteria to be met, the pH had to be :f~-:3 for at least 80% of the
first hour after zinc administration.
Diet
During each treatment phase, the subjects consumed a eucaloric
diet that had a calculated value of 18 mg of zinc per day. The Food
Processor II Nutrient & Diet Analysis System software (ESHA Research,
Salem, OR) was used to calculate the diet and determine energy needs
for each subject. The daily study diet consisted of a total of 720 mL of
Ensure Plus (Ross Laboratories, Columbus, OH), 180 g turkey, 90 g
ham, 135 g white bread, 42 g mayonnaise, 30 g lettuce, and 56 g potato
chips. Varying gram weights of a lemon-lime carbonated beverage and
gumdrop candy were given to make eucaloric adjustments for each
subject. Deionized water was consumed by the subjects during con-
finement in the GCRC. Subjects were allowed to consume tap water at
all other times during the study.
Sample Collection and Analysis
All blood samples were collected in syringes containing zinc-free
heparin and immediately transferred to zinc-free tubes (Falcon, Becton
Dickinson, Lincoln Park, NJ). The samples were centrifuged at 3000
rpm for 10 minutes at 4°C. Plasma fractions were transferred to zinc-
free tubes (Falcon, Becton Dickinson) and stored at -20°C until analy-
sis. Urine was collected in EDTA-washed gallon containers. At the end
of each 24-hour collection, the urine volume was measured and aliquots
were stored in polypropylene tubes with screw caps (Centrifuge Tubes,
Elkay Products, Inc, Shrewsbury, MA) at -20°C until analysis.
Plasma and urinary zinc were determined by flame atomic absorp-
tion spectrophotometry (AAS) (model 451; Instrumentation Laboratory,
Wilmington, MA). Plasma zinc was determined after diluting (1:10) the
samples in 0.5% trace element-free nitric acid. Standards were run every
five samples.
Data and Statistical Analysis
Plasma zinc concentrations for hour 1 through hour 8 were adjusted
for baseline zinc concentration by subtracting the hour 0 concentra-
tion value. When this difference was less than 0, the baseline adjusted
value was set at 0. Total zinc concentration at each dose for each sub-
ject was measured by plasma zinc area under the concentration versus
time curve (AUC) formed by the baseline adjusted values from hour 0
through hour 8. Plasma zinc AUC was calculated using the trapezoidal
rule method 13 as implemented in the TRAP function available in the
BMDP statistical software package (BMDP statistical software manual
to accompany the 1990 software release, W J Dixon, M B Brows, L
Engelman, et al. Berkeley: University of California Press, 1990).
Repeated measures analysis of variance (ANOVA) was used for both
plasma concentration and urinary content to test the null hypothesis
that mean zinc levels for plasma or urine were the same for all four
treatment groups. The alternative hypothesis is that at least one group
was different from the others. Program 2V in BMDP was used for the
repeated measures ANOVA. BMDP was run on a VAX 4000-200 com-
puter.
In Vitro Studies
Dissolution tests were conducted in a rotating basket apparatus’4 to
determine the effect of salt and pH on the dissolution of zinc from zinc
acetate and zinc oxide capsules. Capsules were placed in baskets and
rotated at 50 rpm at 37°C in 900 mL of water. Simulated Gastric Fluid
USP (SGF, without pepsin). and Simulated Intestinal Fluid USP (SIF,
&dquo;without pancreatin). The SGF had a pH of approximately 1.2 and the
SIF had a pH of approximately 7.5. These fluids were chosen to model
the stomach under normal fasting conditions (SGF) and under achlo-
rhydric conditions (SIF). Dissolution of capsules was studied in dupli-
cate in each medium. Ten-milliliter samples of fluid were taken every
15 minutes for 2 hours. with volume replacements, and the samples
were assayed for zinc content by AAS. In vitro samples were collected
in zinc-free tubes (Falcon, Becton Dickinson) and stored at -20°C until
analysis.
RESULTS
The in vitro dissolution results (Table I) indicate that in
both water and SIF ~pH * 7.5), zinc oxide dissolves very
slowly. At the lower pH of SGF (pH = 1.2), both salts
showed increased dissolution, with the effect more pro-
nounced for the oxide.
Two subjects maintained intragastric pH 3 during 78%
of the first hour instead of 80%, in one of the two high pH
phases. The data were included in the analysis because of
the small difference.
Figure 1 illustrates the unadjusted mean plasma zinc
concentration curves. Unadjusted means and standard
deviations for plasma zinc AUC (PZAUC) for each treat-
ment are reported in Table II. The data show that the high-
est plasma zinc concentration occurs with the acetate salt
at low intragastric pH (AL) and the lowest plasma zinc
concentration occurs when the oxide salt is given at the
high intragastric pH (UH). ’1’he plasma zinc concentrations
produced by the administration of the acetate salt during
the high intragastric pH phase (AH) and the oxide salt
during the low intragastric pH phase (OL) are essentially
equivalent.
These plasma results are corroborated by the urine re-
sults, which are shown in Figure 2 and Table III. The high-
est urinary zinc content occurs with the acetate salt at
low intragastric pH (AL) and the lowest urinary znc con-
tent occurs with the oxide salt at high intragastric pH (OH),
while the acetate salt at high intragastric pH (AH) and
oxide salt at low intragastric pH (OL) are essentially
equivalent.
Statistically, the ANOVA indicated a significant differ-
ence between treatments with respect to PZAUC (p < .05).
The ANOVA also indicated an interaction between salt and
pH (p < .05) in their affect on plasma concentration.
Pairwise post-hoc comparisons using the method of Stu-
dent-Newman-Keuls (SNK) detected a significant differ-
ence between the oxide salt at high intragastric pH (OH)
phase and each of the three other phases (p < .05).
TABLE I
Dissolved zinc in water, simulated gastric fluid,
and simulated intestinal fluid
Values in parentheses are percentages.
*Capsules (n = 2) contained 50 mg elemental zinc.
&dquo;’&dquo;Simulated Intestinal Fluid. USP, without pancreatin.
$Simulated Gastric Fluid, USP, without pepsin.
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FiG. 1. Mean plasma zinc response over time to zinc acetate and zinc
oxide administration at low (~3) intragastric pH and high (~5)
intragastric pH (n = 10). ·, zinc acetate at low pH(AL); D, zinc acetate at
high pH(AH); 0, zinc oxide at low pH (OL); 0, zinc oxide at high pH
(OH).
TABLE II
Unadjusted plasma zinc AUC values corresponding to low (<3)
and high (~5) intragastric pH
Values are means ± SD expressed as f-lg X h/dL; number of subjects
= 10.
*Significantly different (p < .05) from zinc oxide at low pH (OL),
zinc acetate at low pH (AL), and zinc acetate at high pH (AH).
The ANOVA also showed that there was a significant
difference between treatments with respect to urinary zinc
content (UZC, p = .01). SNK detected a significant differ-
ence between the acetate salt at low intragastric pH (AL)
and oxide salt at high intragastric pH (OH) phases (p =
.05).
Nausea occurred more frequently with the acetate salt
than with the oxide salt. Fifty percent of the subjects re-
ported nausea during the low pH zinc acetate phase, 70%
experienced nausea during the high pH zinc acetate phase,
20% reported nausea during the low pH zinc oxide phase,
and only 10% were nauseated during the oxide salt at high
intragastric pH phase. The mean duration of nausea and
mean time of onset after the zinc dose was 40 and 80 min-
utes, respectively.
DISCUSSION
The important findings in this study are as follows: (1)
gastric acidity enhances zinc absorption; (2) zinc from the
oxide salt is absorbed to a lesser extent than zinc from the
acetate salt; and (3) zinc absorption from the oxide salt in
a high intragastric pH environment is less than what would
be expected given the individual effects of the oxide salt
and high intragastric pH.
In vitro data suggest that the likely mechanisms for these
findings are the aqueous solubility of the salt and the ef-
fect of pH on dissolution. Zinc oxide is practically insoluble
at a high intragastric pH and the dissolution of zinc oxide
at this pH is extremely low (Table I). Thus, in the absence
FIG. 2. Mean 24-hour urinary zinc excretion in response to zinc acetate
and zinc oxide administration at low (~3) intragastric pH and high (~5)
intragastric pH (n = 8). AL, zinc acetate at low pH; AH, zinc acetate at
high pH; OL, zinc oxide at low pH; OH, zinc oxide at high pH. AL is sig-
nificantly different from OH (~ < .05).
TABLE III
Unadjusted urinary zinc content values of zinc acetate and zinc oxide
corresponding to low (~3) and high (~5) intragastric pH
Values are means -!- SD expressed as mg/d; number of subjects = 8.
*Significantly different (p < .05) from zinc acetate at low pH (AL).
of gastric acidity, a zinc oxide capsule would not be ex-
pected to dissolve well in either the stomach or the intes-
tine, and therefore zinc would not be well absorbed. This
is demonstrated in the in vivo OH data in Tables II and III,
and Figures 1 and 2. In the presence of gastric acidity zinc
oxide is partially solubilized (Table I) and therefore has
greater absorption than at a high intragastric pH (OL vs
OH: Tables II and III, and Figures 1 and 2).
In vitro data also support the hypothesis that gastric
acidity enhances the solubility and dissolution of the ac-
etate salt (Table I). The result, as demonstrated in the in
vivo data, is an increase in zinc absorption (AL vs AH: Table
II and Figure 1). These results are similar to the results of
the 24-hour urinary zinc content found in Table III and Fig-
ure 2.
The clinical implications of these findings are important
because many of the patients taking zinc for the preven-
tion or treatment of disease are in the older age group.
The incidence of hypochlorhydria in patients over age 60
years is estimated to be 31%, with achlorhydria in this age
group estimated at 5% to 10%.15 Other patient populations
likely to have high intragastric pH (pH > 5) include those
taking antacids or gastric acid inhibitors, those with per-
nicious anemia, and patients with AIDS. The results of this
study indicate that there is a risk of decreased zinc ab-
sorption when zinc oxide is used in patients with elevated
intragastric pH.
Well-designed studies that have evaluated the effect of
altered intragastric pH on zinc absorption are lacking in
the literature. To our knowledge the study by Stumiolo et
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al,’O using the sulfate salt, is the only published report that
investigated the in vivo effects of gastric acid inhibition
on zinc absorption. 10 No published data appear to be avail-
able concerning the effects of gastric acid inhibition on
the absorption of zinc from the oxide and acetate salts.
Stumiolo and colleaguesl° found that in healthy volun-
teers, the pharmacologic inhibition of gastric acid secre-
tion significantly reduced the absorption of zinc from an
orally administered zinc sulfate (equivalent to 50 mg of
elemental zinc). In one group, zinc absorption was deter-
mined after an oral dose of zinc sulfate with and without
pretreatment with cimetidine. The zinc AUC was signifi-
cantly decreased after cimetidine compared with no pre-
treatment. A second group received zinc sulfate after pre-
treatment with ranitidine and cimetidine, and with no pre-
treatment. In this group, intragastric acidity was measured
hourly for 6 hours using a nasogastric tube. Ranitidine,
but not cimetidine, significantly increased intragastric pH
compared with no pretreatment. In addition, a statistically
significant reduction in zinc absorption was reported af-
ter ranitidine.
There are several concerns with Sturniolo’s study de-
sign. First, the imidazole group on the cimetidine molecule
has been shown to be a zinc ligandl2 and may increase
zinc absorption. By using famotidine, which has not been
shown to interact with zinc, it was possible to better quan-
titate differences in absorption between low and high
intragastric pH conditions.
Second, the method and frequency of intragastric pH
monitoring that Sturniolo used was unclear. The method
of measuring intragastric pH is critical, because
intragastric pH may fluctuate widely over time. The pre-
ferred method for measuring intragastric pH is continu-
ous monitoring, rather than on an hourly basis. By using
the Heidelberg capsule technique, a continuous monitor-
ing method, we were able to closely monitor the pH dur-
ing the absorptive phase. In our study, the pH values re-
quired for the low (~3) and the high (:-:~5) intragastric pH
phases were maintained during at least 80% of the first
hour after zinc administration, thus assuring that the zinc
would be in the appropriate pH environment during thE
absorptive phase.
Despite the pitfalls of the Sturniolo study,’O our result;
are consistent with theirs. Although Sturniolo used zinc
sulfate and we used zinc acetate, these salts have simila]
solubilities and therefore similar results would be ex
pected.
It is interesting to note that the incidence of nausea wa:
the greatest during the acetate salt phases. The mecha
nism for this adverse event is unclear, but may be due t<
local irritation.
In conclusion, this study indicates that the oxide salt i:
not an appropriate zinc salt to use in those patients wh4
are hypochlorhydric or achlorhydric. Zinc acetate was ab
sorbed more consistently and is the preferred zinc salt to
use in patients with AIDS, pernicious anemia, in patients
on gastric acid inhibitors, and in the elderly.
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